Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $27.15 USD
Change Today +0.63 / 2.38%
Volume 312.7K
QDEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Key Developments

Quidel Corporation Receives FDA Clearance for its Amplivue Trichomonas Assay

Quidel Corporation announced that it has received clearance from the United States Food and Drug Administration (FDA) to market its AmpliVue Trichomonas Assay for the detection of nucleic acids isolated from clinician-collected vaginal swab specimens obtained from symptomatic or asymptomatic female patients. This molecular assay aids in the diagnosis of trichomoniasis, a sexually transmitted disease attributable to infection by the Trichomonas vaginalis parasite. The AmpliVue Trichomonas Assay is an easy-to-use, self-contained, handheld disposable molecular diagnostic test with superb clinical accuracy and with procedural steps consistent with those commonly seen in moderately complex laboratories. Quidel's AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests. The AmpliVue Trichomonas Assay is Quidel's sixth molecular infectious disease assay to receive 510(k) clearance from the FDA in this hand-held, disposable AmpliVue format. In addition to Trichomonas Quidel offers 510(k)-cleared, in vitro diagnostic products on this novel platform for the diagnosis of six other pathogens: C. difficile, Group A Strep, Group B Strep, Pertussis, HSV1 and HSV2.

Quidel Corp. Approves Amendments to the Bylaws

On February 24, 2015, the board of directors of Quidel Corporation amended and restated the company's bylaws to add as a new Article VII a forum selection provision identifying Delaware as the exclusive forum for the adjudication of certain intra-corporate disputes. The adoption of the forum selection provision is effective as of February 24, 2015.

Quidel Corp. Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM

Quidel Corp. Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Douglas C. Bryant, Chief Executive Officer, President and Director.

Quidel Corp. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 11:20 AM

Quidel Corp. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 11:20 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Douglas C. Bryant, Chief Executive Officer, President and Director.

Quidel Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Quidel Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company's total revenues were USD 63,597,000 compared to USD 50,170,000 a year ago. Operating income was USD 12,915,000 compared to USD 236,000 a year ago. Income before taxes was USD 12,095,000 compared to loss before taxes of USD 89,000 a year ago. Net income was USD 7,113,000 or USD 0.20 per diluted share compared to USD 1,139,000 or USD 0.03 per diluted share a year ago. Adjusted net income was USD 13,336,000 or USD 0.37 per diluted share compared to USD 6,963,000 or USD 0.20 per diluted share a year ago. The increase in Revenue was due to greater sales of Infectious Disease products in the fourth quarter of 2014. For the year, the company's total revenues were USD 182,615,000 compared to USD 175,410,000 a year ago. Operating loss was USD 9,208,000 compared to operating income of USD 4,842,000 a year ago. Loss before taxes was USD 10,983,000 compared to income before taxes of USD 3,434,000 a year ago. Net loss was USD 7,074,000 or USD 0.21 per diluted share compared to net income of USD 7,390,000 or USD 0.21 per basic and diluted share a year ago. Adjusted net income was USD 12,342,000 or USD 0.35 per diluted share compared to USD 21,348,000 or USD 0.61 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $27.15 USD +0.63

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $13.29 USD +0.20
Ion Beam Applications €21.07 EUR +0.79
Luminex Corp $16.10 USD +0.32
Meridian Bioscience Inc $19.12 USD -0.01
OraSure Technologies Inc $6.19 USD -0.29
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book 3.8x
Price/Cash Flow 533.4x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.